Pharmacogenomics in Dermatology: HLA Typing and Drug Reactions
Pharmacogenomics in dermatology focuses on the relationship between an individual's genetic makeup and their response to dermatological medications, particularly concerning HLA typing and drug reactions. Understanding these genetic factors can help predict adverse drug reactions and guide personalized treatment approaches in dermatology.
Topics: pharmacogenomics, HLA, SJS
Overview / Definition Pharmacogenomics is the study of how genes affect a person's response to drugs. In dermatology, it is crucial for understanding adverse drug reactions (ADRs) that can arise from systemic medications, particularly in conditions like psoriasis, eczema, and drug-induced hypersensitivity reactions. HLA typing refers to the testing of human leukocyte antigen (HLA) genes that encode proteins critical for immune system function, which can be associated with severe drug reactions. Epidemiology Adverse drug reactions in dermatology are not uncommon, with estimates suggesting that they account for 2-5% of hospital admissions. Specific HLA alleles have been linked to increased susceptibility to drug reactions: HLA-B*57:01 - associated with hypersensitivity to abacavir. HLA-B*15:02 - linked to Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) with carbamazepine and other anticonvulsants. HLA-A*3101 - associated with SJS/TEN in patients taking carbamazepine, especially in Asian populations. Pathophysiology / Mechanism The pathophysiology of drug reactions related to HLA typing involves complex immunological mechanisms. Drug metabolites can bind to HLA molecules, presenting altered peptides that activate T-cells, leading to an immune response. This process can result in various skin manifestations: Exanthematous drug eruption Stevens-Johnson syndrome Drug-induced lupus erythematosus Understanding these mechanisms is critical for predicting and preventing ADRs. Clinical Presentation Drug reactions can present in various forms, including: Exanthematous drug eruptions: maculopapular rashes occurring usually 1-2 weeks after drug initiation. Stevens-Johnson syndrome/TEN: severe blistering and mucosal involvement, often requiring hospitalization. Fixed drug eruptions: localized lesions that recur at the same site upon re-exposure to the offending drug. Recognizing these presentations is essential for timely management and potential discontinuatio